EI
NUVB icon

EAM Investors’s Nuvation Bio NUVB Stock Holding History

EAM Investors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-404,019
Closed -$3.62M – 346
2025
Q4 		$3.62M Buy
+404,019
New +$2.5M 0.4% 132
2024
Q3 		– Sell
-182,876
Closed -$534K – 302
2024
Q2 		$534K Sell
182,876
-41,175
-18% -$126K 0.09% 225
2024
Q1 		$816K Buy
+224,051
New +$430K 0.13% 199

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EAM Investors's NUVB Position: Q1 2026 in Review

EAM Investors sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 404,019 shares — an estimated $3.62M sold.

EAM Investors first reported a position in NUVB in Q1 2024 and held it in 3 quarters. The position peaked at $3.62M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • EAM Investors reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 404,019 Nuvation Bio shares in Q1 2026, an estimated $3.62M.
  • EAM Investors first reported a position in Nuvation Bio in Q1 2024 and held it in 3 quarters.
  • EAM Investors's Nuvation Bio position peaked at $3.62M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.